Maher Albitar

Summary

Affiliation: Quest Diagnostics
Country: USA

Publications

  1. doi request reprint Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease
    Kevin Z Qu
    Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92675, USA
    J Gastroenterol Hepatol 26:751-8. 2011
  2. pmc Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations
    Tai Sung Lee
    Biomedical Informatics and Computational Biology, and Department of Chemistry, University of Minnesota, 207 Pleasant Street, S E, Minneapolis, MN 55455, USA
    BMC Struct Biol 9:58. 2009
  3. doi request reprint Proteomics-based prediction of clinical response in acute myeloid leukemia
    Maher Albitar
    Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690 6130, USA
    Exp Hematol 37:784-90. 2009
  4. ncbi request reprint Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy
    M Albitar
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690, USA
    Leukemia 21:480-8. 2007
  5. ncbi request reprint Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease
    Maher Albitar
    Quest Diagnostics Nichols Institute, 33608 Ortega Highway, Rm 108B, San Juan Capistrano, CA 92690 6130, United States
    Leuk Res 31:139-45. 2007
  6. ncbi request reprint Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies
    Maher Albitar
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690 6130, USA
    Cancer 101:999-1008. 2004
  7. ncbi request reprint Myelodysplastic syndrome: from morphology to biology
    Maher Albitar
    Quest Diagnostics Nichols Institute, 33608 Ortega Highway, Room 108B, San Juan Capistrano, CA 92690, USA
    Curr Hematol Rep 3:159-64. 2004
  8. doi request reprint Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome
    Wanlong Ma
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, California, USA
    Clin Cancer Res 15:3820-6. 2009
  9. ncbi request reprint An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation
    Iman Jilani
    Department of Hematology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690, USA
    Leuk Res 32:936-43. 2008
  10. doi request reprint Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia
    Jean Marie Bruey
    Hematology, Quest Diagnostics Nichols Institute, Building A, Hematopathology Oncology R and D, 33608 Ortega Highway, San Juan Capistrano, CA 92675, United States
    Leuk Res 34:173-6. 2010

Detail Information

Publications96

  1. doi request reprint Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease
    Kevin Z Qu
    Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92675, USA
    J Gastroenterol Hepatol 26:751-8. 2011
    ..Recent reports suggested a link between abnormalities in the ubiquitin-proteasome system (UPS) and HCC. We investigated the potential of using UPS markers, along with HCC markers, to differentiate HCC from chronic liver disease (CLD)...
  2. pmc Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations
    Tai Sung Lee
    Biomedical Informatics and Computational Biology, and Department of Chemistry, University of Minnesota, 207 Pleasant Street, S E, Minneapolis, MN 55455, USA
    BMC Struct Biol 9:58. 2009
    ....
  3. doi request reprint Proteomics-based prediction of clinical response in acute myeloid leukemia
    Maher Albitar
    Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690 6130, USA
    Exp Hematol 37:784-90. 2009
    ..The ability to predict responders may help in stratifying patients and exploring different therapeutic approaches for nonresponders. Proteomics methods were used to search for predictive factors or combinations of factors...
  4. ncbi request reprint Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy
    M Albitar
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690, USA
    Leukemia 21:480-8. 2007
    ..sHLA-I has been reported to be an immunomodulator inhibiting the cytotoxic effects of T-lymphocytes, which may offset its predictive value for disease aggressiveness in patients with MDS...
  5. ncbi request reprint Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease
    Maher Albitar
    Quest Diagnostics Nichols Institute, 33608 Ortega Highway, Rm 108B, San Juan Capistrano, CA 92690 6130, United States
    Leuk Res 31:139-45. 2007
    ..Further studies are needed to assess whether the immunomodulatory properties of sHLA-I may be responsible for its divergence from beta2M as an indicator of clinical behavior in HD...
  6. ncbi request reprint Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies
    Maher Albitar
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690 6130, USA
    Cancer 101:999-1008. 2004
    ..The authors investigated the possibility that CD52 may be shed from cells and, once soluble, may bind to injected alemtuzumab, forming immune complexes...
  7. ncbi request reprint Myelodysplastic syndrome: from morphology to biology
    Maher Albitar
    Quest Diagnostics Nichols Institute, 33608 Ortega Highway, Room 108B, San Juan Capistrano, CA 92690, USA
    Curr Hematol Rep 3:159-64. 2004
    ..New therapeutic agents that target histone deacetylation, DNA methylation, or angiogenesis show promise, but focused biologic and therapeutic studies are needed to improve the outcome of this disease...
  8. doi request reprint Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome
    Wanlong Ma
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, California, USA
    Clin Cancer Res 15:3820-6. 2009
    ..Because clinical outcomes vary markedly within cytogenetic subgroups, additional biological markers are needed for risk stratification...
  9. ncbi request reprint An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation
    Iman Jilani
    Department of Hematology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690, USA
    Leuk Res 32:936-43. 2008
    ..This technique is useful in monitoring patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL), but the same approach can be used in other translocations and has the potential of multiplexing...
  10. doi request reprint Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia
    Jean Marie Bruey
    Hematology, Quest Diagnostics Nichols Institute, Building A, Hematopathology Oncology R and D, 33608 Ortega Highway, San Juan Capistrano, CA 92675, United States
    Leuk Res 34:173-6. 2010
    ..05). These findings suggest that Ki-67 can be detected in circulation and has potential for use as a biomarker for predicting clinical behavior in ALL...
  11. doi request reprint Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia
    Wanlong Ma
    Department of Hematology, Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92675, USA
    Cancer 112:1306-12. 2008
    ..The ubiquitin-proteasome pathway has been implicated in the pathogenesis of many hematologic malignancies...
  12. ncbi request reprint Differences in CD33 intensity between various myeloid neoplasms
    Iman Jilani
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 118:560-6. 2002
    ..There was no correlation between CD33 intensity and response to therapy or overall survival in 35 patients treated with protocols including Mylotarg. These data demonstrate variation in CD33 intensity between various leukemias...
  13. ncbi request reprint Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy
    Iman Jilani
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA
    Leuk Res 32:643-9. 2008
    ..These observations suggest that imatinib- resistance is not necessarily dependent on higher activity in BCR-ABL-dependent pathways, but is likely due to the activation of other pathways...
  14. doi request reprint Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia
    Chen Hsiung Yeh
    Department of Hematopathology, 33608 Ortega Highway, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690, United States
    Leuk Res 33:212-7. 2009
    ..Plasma Hsp70 thus could be a potential marker for predicting disease progression in patients with chronic phase CML...
  15. ncbi request reprint Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia
    Raymond Lai
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Cancer 95:1071-5. 2002
    ..The purpose of this study is to fully assess the prognostic value of IL-6 in CLL patients...
  16. pmc Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias
    Wanlong Ma
    Hematopathology Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92675, USA
    J Mol Diagn 11:49-53. 2009
    ..Furthermore, mutation screening using RNA is highly sensitive and could replace DNA-based testing because of the relative abundance of target transcripts and the ease in detecting deletion of the entire exon...
  17. ncbi request reprint Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance
    Taghi Manshouri
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    Blood 101:2507-13. 2003
    ..01). The prognostic value of cCD20 was independent of Rai staging or hemoglobin level. Prospective evaluation is indicated to establish whether rituximab dosing should be adjusted according to cCD20 levels...
  18. ncbi request reprint The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome
    Di Lu
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:441-9. 2003
    ....
  19. ncbi request reprint Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes
    Qinglong Hu
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 100:1884-91. 2004
    ..Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) are major regulators of angiogenesis, which plays a key role in the growth and dissemination of solid tumors and hematologic neoplasms...
  20. ncbi request reprint Myelodysplastic syndrome is not merely "preleukemia"
    Maher Albitar
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston 77030 4095, USA
    Blood 100:791-8. 2002
    ....
  21. doi request reprint Circulating CD33 and its clinical value in acute leukemia
    Adam Abdool
    Hematology and Oncology Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA
    Exp Hematol 38:462-71. 2010
    ..CD33 is a cell surface antigen for committed myelomonocytic lineage. We explored the potential of detecting CD33 as cell-free circulating protein in patients with leukemia...
  22. pmc Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome
    Wanlong Ma
    Department of Hematology Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    BMC Med Genet 11:163. 2010
    ..The G/G genotype of the single-nucleotide polymorphism (SNP) rs1617640 in the erythropoietin (EPO) promoter has been shown to be associated with decreased EPO expression. We examined the association of rs1617640 genotype with MDS...
  23. doi request reprint Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia
    Jean Marie Bruey
    Department of Hematology and Oncology R and D, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690, USA
    Leuk Res 34:1320-4. 2010
    ..The results of this study suggest that the plasma cKi-67 index, along with B2M level, is a strong predictor of clinical behavior in CLL...
  24. doi request reprint Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance
    Wanlong Ma
    Department of Hematopathology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92675, USA
    Leuk Res 35:526-33. 2011
    ..The Ch-L activity when normalized to the level of proteasome protein show significant negative correlation with survival in ALL...
  25. doi request reprint Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications
    Wanlong Ma
    Hematopathology Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA
    Cancer Biomark 5:51-8. 2009
    ..These data underline the significance of NPM1 in the biology and clinical behavior of AML, and demonstrate the reliability and efficacy of plasma-based testing for NPM1 mutations...
  26. ncbi request reprint Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia
    Maher Albitar
    Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690, USA
    Cancer 106:1587-94. 2006
    ..However, unlike pediatric ALL, recurrence is common in adult ALL, and the ability to predict at an early stage which patients are most likely to experience recurrence may help in devising new therapeutic approaches to prevent recurrence...
  27. ncbi request reprint Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
    Iman Jilani
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 102:3514-20. 2003
    ..The importance of this down-modulation in the efficacy of current therapy with rituximab needs further investigation...
  28. ncbi request reprint Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia
    Wanlong Ma
    Quest Diagnostics Nichols Institute 33608 Ortega Highway, Rm 108B, San Juan Capistrano, CA 92690 6130, USA
    Haematologica 92:170-5. 2007
    ..Peripheral blood plasma was analyzed in this study because of previous detection of nucleic acids and proteins from tumor cells in plasma samples...
  29. ncbi request reprint Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome
    Hesham M Amin
    Department of Hematopathology, Box 72, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:1866-8. 2003
    ..Our findings suggest that the alterations in B lymphocytes in the form of increased apoptosis can be seen in MDS and support the concept that immune modulation plays a role in the pathophysiology of MDS...
  30. ncbi request reprint Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay
    Iman Jilani
    Department of Hematopathology, Nichols Institute, Quest Diagnostics, 33608 Ortega Highway, Rm 108B, San Juan Capistrano, CA 92690 6130, USA
    Leuk Res 28:1255-62. 2004
    ..This validated assay should help optimize the dosing and scheduling of alemtuzumab therapy. The underlying principles are also applicable to the measurement of other humanized antibodies using an appropriate anti-Ig...
  31. ncbi request reprint Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma
    Maha Ahmed
    Department of Hematopathology, M D Anderson Cancer Center, The University of Texas, Houston, TX 77030 4095, USA
    Eur J Haematol 71:174-8. 2003
    ..However, cytogenetic analysis in MM is frequently difficult because of poor yield of informative metaphases and the disease is frequently patchy, which complicates fluorescent in situ hybridization studies...
  32. doi request reprint MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders
    Wanlong Ma
    Department of Hematology Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA
    Diagn Mol Pathol 20:34-9. 2011
    ..3 JAK2 exon 12 mutations, and 1.3 JAK2 exons 13 to 14 mutations. These findings suggest that MPL mutation screening should be performed before JAK2 exons 12 to 14 testing in JAK2 V617F-negative patients with suspected MPDs...
  33. ncbi request reprint Measuring humanized antibodies in plasma of patients treated with antibody-based therapy using bead-based flow cytometry: the story of alemtuzumab
    Huai En Huang Chan
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    Methods Mol Biol 378:159-65. 2007
    ..This approach is applicable to the measurement of other humanized antibodies that contain an appropriate remnant animal sequence...
  34. ncbi request reprint A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry
    Joanne Bareng
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA
    Leuk Lymphoma 48:2189-95. 2007
    ..Flow-cytometry-based assays for JAK/STAT signaling pathway and HSPs are likely to have broad clinical utility for monitoring patients with abnormalities in the JAK2 pathway...
  35. doi request reprint Clinical correlation of circulating heat shock protein 70 in acute leukemia
    Chen Hsiung Yeh
    Department of Oncology Hematology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690, USA
    Leuk Res 34:605-9. 2010
    ..04) and ALL (P=0.05), suggesting that in these two acute diseases, cHSP70 is an indicator for poor prognosis. Our data support the potential of using free cHSP70 as a biomarker in leukemias and potentially other types of cancers...
  36. ncbi request reprint The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia
    Yupo Ma
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 100:2167-75. 2004
    ....
  37. ncbi request reprint Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome
    Raymond Lai
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 94:14-7. 2002
    ..Endostatin, a C-terminal fragment of collagen XVIII, is an endogenous angiogenesis inhibitor. While endostatin is being investigated for its usefulness in treating solid tumors, its significance in hematologic malignancies is unknown...
  38. ncbi request reprint Monitoring cell signaling pathways by quantitative flow cytometry
    Huai En Huang Chan
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    Methods Mol Biol 378:83-90. 2007
    ..As an example, total and phosphorylated CRKL is quantitated. The methodology has the potential for widespread application in the monitoring of targeted therapy...
  39. ncbi request reprint Detection of chromosome translocations by bead-based flow cytometry
    Huai En Huang Chan
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    Methods Mol Biol 378:167-74. 2007
    ..This approach has the potential for widespread application in the detection and quantitation of other fusion genes involved in hematological malignancies...
  40. doi request reprint Plasma-based detection of clonality in lymphoid malignancies
    Chen Hsiung Yeh
    Department of Hematopathology R and D, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    Eur J Haematol 82:450-3. 2009
    ..We assessed the utility of plasma as a DNA source for detection of genetic abnormalities in patients with suspected B- or T-cell lymphoproliferative disorders...
  41. ncbi request reprint Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome
    Chung Wu Lin
    Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, 1515 Holcombe Blvd, P O Box 72, Houston, TX 77030, USA
    Leuk Res 26:551-9. 2002
    ..Our results illustrate differences in proliferation and apoptosis between acute and chronic leukemias and MDS. These differences may have diagnostic and therapeutic implications...
  42. doi request reprint Cell-free bead-based detection of total and phosphorylated proteins in plasma and cell lysates: detection of FLT3
    Huai En Huang Chan
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    Methods Mol Biol 378:153-7. 2007
    ..Fms-like tyrosine kinase-3, which is mutated in majority of cases of acute myeloid leukemia, is used as an example. This method could be applied to the quantitation of several other proteins without the need for intact cells...
  43. doi request reprint Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer
    Heather R Sanders
    Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    Cancer Genet 204:45-52. 2011
    ..This RT-PCR-based exon scanning approach avoids the limitations of screening only for previously identified EML4-ALK fusions and provides a simple molecular assay for fusion detection in a clinical diagnostics setting...
  44. ncbi request reprint He use of the antibodies in the diagnosis of leukemia and lymphoma by flow cytometry
    Mohammad Reza Sheikholeslami
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    Methods Mol Biol 378:53-63. 2007
    ..Here, we describe a methodology for using flow cytometry with six colors for the analysis of various tissues for hematological diseases...
  45. pmc JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms
    Wanlong Ma
    Department of Hematology Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, California, USA
    PLoS ONE 5:e12165. 2010
    ..This appears to be an alternative splicing mutation, not detectable with DNA-based testing...
  46. ncbi request reprint Quantification of intracellular proteins and monitoring therapy using flow cytometry
    Richard L Chang
    Hematology and Oncology Department, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92675, USA
    Curr Drug Targets 11:994-9. 2010
    ..Advances in this technology: high-throughput capability and automation, making it a valuable platform in modern drug discovery...
  47. doi request reprint Somatic mutations of signaling genes in non-small-cell lung cancer
    Heather R Sanders
    Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92675, USA
    Cancer Genet Cytogenet 203:7-15. 2010
    ....
  48. ncbi request reprint Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia
    LaBaron T Washington
    Department of Hematopathology, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, P O Box 72, Houston, TX 77030 4095, USA
    Leuk Res 26:899-902. 2002
    ..008) and decreased annexin V positivity (P=0.01). Our results suggest that lower apoptosis in 5q-syndrome may explain the milder clinical course of the disease and distinguish 5q-syndrome from other MDS...
  49. ncbi request reprint Chronic lymphocytic leukemia with t(14;18) and trisomy 12
    Filiz Sen
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Arch Pathol Lab Med 126:1543-6. 2002
    ..To conclude, cases of CLL carrying t(14;18) are exceedingly rare, and +12 appears to be the most common cytogenetic abnormality coexisting with t(14;18) in CLL...
  50. ncbi request reprint Quantification of surface antigens and quantitative flow cytometry
    Huai En Huang Chan
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    Methods Mol Biol 378:65-9. 2007
    ..We describe a quantitative flow cytometry approach to measuring levels of the CD20 surface antigen, the molecular target of rituximab...
  51. doi request reprint Circulating microRNAs as biomarkers for hepatocellular carcinoma
    Kevin Z Qu
    Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA
    J Clin Gastroenterol 45:355-60. 2011
    ....
  52. doi request reprint Liquid-based fluorescence in situ hybridization assay for detection of ERBB2 gene amplification in patients with breast cancer
    Chen Hsiung Yeh
    Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675 2042, USA
    Clin Chem 54:1831-9. 2008
    ..We developed and evaluated a novel, quantitative liquid-based FISH (L-FISH) assay that uses flow cytometry to detect ERBB2 gene amplification in breast cancer patients...
  53. ncbi request reprint Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia
    William G Wierda
    Department of Leukaemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 120:452-6. 2003
    ..The role of IL-8 inhibitors in the treatment of patients with CLL should be explored...
  54. ncbi request reprint A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1234-41. 2003
    ....
  55. ncbi request reprint Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
    Apostolia Tsimberidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1481-7. 2003
    ....
  56. ncbi request reprint SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:795-801. 2003
    ..Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML/MDS...
  57. ncbi request reprint The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia
    Alessandra Ferrajoli
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:1215-9. 2002
    ..005). We conclude that the TNF-alpha level serves as a prognostic factor in patients with CLL and that inhibition of TNF-alpha in these patients could have therapeutic importance...
  58. ncbi request reprint Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
    Alvaro Aguayo
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 95:1923-30. 2002
    ..Increased levels in urine, serum, plasma, or malignant tissue have been associated with an adverse prognosis in patients with solid tumors...
  59. ncbi request reprint Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome
    Srdan Verstovsek
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 118:151-6. 2002
    ..These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS...
  60. ncbi request reprint Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes
    Francis J Giles
    The University of Texas, M D Anderson Cancer Center, Department of Leukemia, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Leuk Res 29:649-52. 2005
    ..There was no significant impact on CR rates, TTF, survival, or toxicity of adding an IL-11 regimen to IA induction in patients >/=50 years of age with AML...
  61. ncbi request reprint Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    Michael J Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3554-61. 2002
    ..Alemtuzumab induced significant responses in these patients with clinical benefit in the majority and with acceptable toxicity in a high-risk group...
  62. ncbi request reprint Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3547-53. 2002
    ..04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML...
  63. ncbi request reprint Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    William Wierda
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:4070-8. 2005
    ..The purpose of this study was to improve the complete remission (CR) rate for previously treated patients and evaluate the quality of bone marrow response...
  64. ncbi request reprint Emerging information on the use of rituximab in chronic lymphocytic leukemia
    Michael J Keating
    Leukemia Department, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 29:70-4. 2002
    ....
  65. ncbi request reprint Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels
    Sima Jeha
    Department of Pediatrics, University of Texas, M D Anderson Cancer Center, P O Box 072, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 26:399-402. 2002
    ..Unlike in adults, VEGF and VEGF-R2 levels in pediatric AML patients did not correlate with survival. This data suggest that the role of VEGF and its receptor VEGF-R2 in pediatrics AML may be different from that in adult AML...
  66. ncbi request reprint Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
    Apostolia M Tsimberidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1711-20. 2003
    ..A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) in these patients...
  67. ncbi request reprint Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia
    Sherif Ibrahim
    Section of Molecular Hematopathology, New York University, New York, New York, USA
    Cancer 97:1914-9. 2003
    ..In the current study, blood samples from patients with B-CLL were examined to identify CD31 surface marker expression, and CD31 expression was correlated with several other known prognostic variables, including CD38...
  68. ncbi request reprint Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1794-803. 2006
    ..Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters...
  69. ncbi request reprint Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia
    Charles Koller
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, USA
    Blood 108:1001-6. 2006
    ..95 mg/L had significantly shorter survival than those with lower values. Plasma TPO and beta2-M may be useful for the prediction of clinical behavior in CLL and may replace the need for the determination of IgV(H) mutation status...
  70. ncbi request reprint Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia
    Deborah A Thomas
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Br J Haematol 123:436-41. 2003
    ..Thalidomide analogues with more potent immunomodulatory activities and more favourable toxicity profiles may offer more promise as anti-AML therapy...
  71. ncbi request reprint Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 123:850-7. 2003
    ..The clinical significance of circulating antigen in patients receiving monoclonal antibody therapy directed against CD20 and/or CD52 warrants study...
  72. ncbi request reprint Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 11:7817-24. 2005
    ..A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease...
  73. ncbi request reprint Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:6615-24. 2005
    ..A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...
  74. ncbi request reprint Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia
    Srdan Verstovsek
    Department of Leukemia, M D Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA
    Leuk Res 28:707-11. 2004
    ..5 and 0.04, respectively) as compared with patients with detectable TA. However, there was no correlation between TA and survival. This data suggests that TA may not play a significant role in the clinical behavior of CLL...
  75. ncbi request reprint Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
    Susan M O'Brien
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2657-63. 2003
    ..The objective of this study was to investigate the efficacy and safety of alemtuzumab, the humanized anti-CD52 monoclonal antibody, in patients with B-cell chronic lymphocytic leukemia and residual disease after chemotherapy...
  76. ncbi request reprint Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
    Michael J Keating
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:4079-88. 2005
    ..A chemoimmunotherapy program consisting of fludarabine, cyclophosphamide, and rituximab (FCR) was developed with the goal of increasing the complete remission (CR) rate in previously untreated CLL patients to >/= 50%...
  77. ncbi request reprint Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma
    Maurizio Zangari
    University of Arkansas for Medical Sciences, The Multiple Myeloma Institute for Research and Therapy, Little Rock, Arkansas, USA
    Clin Cancer Res 10:88-95. 2004
    ..SU5416 is a small molecule VEGF receptor 2 inhibitor. Experimental Design: Adult patients with advanced MM were entered on a multicenter phase II study...
  78. ncbi request reprint A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia
    Francis Giles
    Leuk Res 30:1591-5. 2006
    ..3 months) in the study cohort was directly comparable to that of 233 matched patients treated with other single agents. The study cloretazine regimen had minimal activity in a very high risk subset of patients with relapsed AML...
  79. ncbi request reprint Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
    Karen W L Yee
    Authors Affiliations Departments of Leukemia and Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 12:5165-73. 2006
    ..A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malignancies...
  80. ncbi request reprint Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:2760-6. 2003
    ..c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated in the pathogenesis of myeloproliferative disorders (MPD)...
  81. ncbi request reprint Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
    Apostolia Tsimberidou
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Leuk Res 27:893-7. 2003
    ..CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML...
  82. ncbi request reprint The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
    Francis J Giles
    Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 136:624-7. 2007
    ..001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy...
  83. ncbi request reprint The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cancer 98:1681-8. 2003
    ..Levels of the soluble form of CD86 (sCD86) are elevated in a proportion of patients with leukemia. Although it is a potential modulator of antitumor responses, the significance of sCD86 in patients with hematologic malignancies is unknown...
  84. doi request reprint The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1605-13. 2008
    ..In the current study, the authors assessed the association between serum levels of various cytokines and clinical outcomes in patients with untreated AML or high-risk MDS...
  85. ncbi request reprint A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Francis Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4628-35. 2006
    ..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
  86. ncbi request reprint Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma
    Francis J Giles
    Department of Leukemia, MD Anderson Cancer Center, The University of Texas, PO Box 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 28:595-604. 2004
    ..In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HD...
  87. ncbi request reprint Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, 77230 1402, USA
    Br J Haematol 134:58-60. 2006
    ..The EPI is reproducible and useful...
  88. ncbi request reprint Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cancer 106:2148-57. 2006
    ..Although soluble CD40 (sCD40) is a potential modulator of both antitumor responses and CD40-based therapies, the levels and significance of sCD40 in patients with hematologic malignancies are unknown...
  89. ncbi request reprint Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 100:1449-58. 2004
    ..OSI-211 is a low-clearance, unilamellar liposomal formulation of a water-soluble camptothecin analogue, lurtotecan. OSI-211 has significant activity in severe combined immunodeficient mouse models of human leukemia...
  90. ncbi request reprint Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia
    Anne Marie O'Farrell
    SUGEN Inc, South San Francisco, CA, USA
    Leuk Res 28:679-89. 2004
    ..The translational and clinical analyses described in this report provide some insights into the mechanism and duration of action of SU5416...
  91. ncbi request reprint Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia
    Srdan Verstovsek
    Department of Leukemia and Hematopathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 72, Houston, TX 77030, USA
    Blood 99:2265-7. 2002
    ..008). Multivariate analysis showed that VEGF was not independent of the synthesis stage (P =.09). These data suggest that VEGF plays a role in the biology of CML and that VEGF inhibitors should be investigated in CML...
  92. ncbi request reprint Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome
    Christina A Meyers
    Department of Neurooncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:788-93. 2005
    ..The objective of the current study was to assess the correlations between cognitive function, fatigue, quality of life, and circulating cytokine levels in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)...
  93. ncbi request reprint C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome
    Anne S Tsao
    MD Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, P O Box 428 Houston, TX 77030, USA
    Leuk Res 28:373-8. 2004
    ..However, after accounting for these covariates, multivariate analysis indicates that higher c-kit expression predicts higher CR rates, although there was no effect on DFS in CR...
  94. ncbi request reprint Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
    Jorge Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:1692-7. 2003
    ..R115777 showed clinical activity in patients with CML and MF. The effect on VEGF needs to be further investigated to determine whether this might be a possible mechanism of action of R115777...
  95. ncbi request reprint Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:1287-92. 2004
    ....
  96. ncbi request reprint Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2212-7. 2003
    ..The impact of elevated TA on the course of pediatric patients with acute myeloid leukemia (P-AML) is unknown...